Abstract
The kynurenine pathway (Fig. 3) . These metabolites are usually referred to as neuroactive KYNs [27, 28] . KYNA is an antagonist of the strychnine-insensitive glycine-binding site of the N-methyl-D-aspartate (NMDA) receptor [29, 30] , a weak antagonist of ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainite receptors [31] and also an inhibitor of the ␣7 nicotinic receptor [32] , which is involved in the pre-synaptic regulation of glutamate (L-Glu) release. Conversely, the neuroinhibitory effect of KYNA is concentration dependent: in nanomolar concentrations, it facilitates field excitatory postsynaptic potentials (EPSPs) [33] . QUINA is neurotoxic [34] , and has been shown to be a direct activator of NMDA receptors [35] , to modulate the release or reuptake inhibition of L-Glu [36] and to be involved in lipid peroxidation [37, 38] and the production of reactive oxygen species (ROS) [38, 39] . 3 [39] [40] [41] [42] . KYNA production in the different species [46] [59] [60] [61] [62] , multiple sclerosis [63, 64] , focal dystonia [65] and migraine [66] [67] [68] [69] . An increasing body of evidence indicates that the KYN pathway is involved in the pathogenesis of AD [70, 71] . Baran found slight decreases in the KYN and 3-OH-KYN levels in patients with pathologically confirmed AD [71] . A markedly increased content of KYNA was found selectively in the caudate nucleus and the putamen, which was correlated with increased KAT I activity. The level of aspartate aminotransferase in the cerebrospinal fluid (CSF) was found to be elevated in AD patients [72] . The mitochondrial form of the enzyme was identified as KAT IV [46] . The serum and red blood cell KYNA levels were decreased in AD patients, but there was no alteration in the KAT I or II activity [73] . Furthermore, the serum KYN/TRP ratio was found to be increased in AD patients, indicating and enhanced activity of IDO, the first key enzyme of the pathway [70] . Interestingly the TRP/KYN ratio also proved to be correlated with the cognitive performance of the patients [70] . Another study demonstrated lower KYNA concentration in the lumbar CSF in AD patients [74] . No alteration in QUINA was found either in the CSF [74] or in the examined cortical, subcortical or cerebellar structures [75] . A␤1-42 induced the expression of IDO and a significant increase in QUINA in human macrophages and microglia [76] , but no similar effect of A␤1-40 was found [77] . A human AD brain preparation involving a subset of senile plaques displayed IDO and QUINA immunoreactivity, and these plaques were characterized by high microglia and reactive astrocytic contents [44] . [82] , lipid peroxidation [83] , free carbonyls [81] and peroxynitration [84] [85] .
Neuroactive kynurenines

The kynurenine (KYN) pathway is the major route for the metabolism of the essential amino acid tryptophan (TRP) [26], the final product of which is nicotinamide adenosine dinucleotide (NAD) (Fig. 3). The first stable metabolite of the pathway is KYN, which is transformed either by KYN aminotransferase (KAT) to kynurenic acid (KYNA) or by KYN hydroxylase to 3-hydroxykynurenine (3-OH-KYN), which is further metabolized to quinolinic acid (QUINA), the precursor of NAD
-OH-KYN also leads to cell death involving apoptotic features by generating ROS
Connection of oxidative stress and kynurenines
A close connection between APP/A␤ and the mitochondria had already been established. The APP and A␤ were found to be associated with the mithochondrial membrane [86, 87] and to bind to the mitochondrial matrix protein [88] . A␤1-42 inhibits cytochrome oxidase activity in a Cu-dependent manner [89] . Devi [97] . Another study raised the possibility that the lipid peroxidation effect of QUINA depends on iron and is likely to involve iron chelation by QUINA [98] . QUINA not only induces oxidative stress through the production of ROS, but also appears to influence the antioxidative mechanisms. The concentrations of reduced (GSH) and oxidized (GSSG) glutathione were decreased and increased, respectively, whereas the level of glutathione peroxidase remained stable, indicating a nonenzymatic conversion of GSH to GSSG [99] . The same study also showed that the cytosolic Cu/Zn SOD activity decreased, whereas the mitochondrial Mn SOD was unchanged after intrastriatal QUINA treatment [99] , signifying the immediate cytoplasmatic effects of QUINA. Although ROS production seems to be a general feature of QUINA treatment, the lipid peroxidation effect is regionally specific in rat synaptosomes: the striatum and hippocampus displayed increased production of peroxidized lipids after QUINA treatment [38] . Furthermore, lipid peroxidation and oxidative stress could be antagonized by N-nitro-L-arginine, a selective antagonist of nitrogen monoxide synthase [100] . N-nitro-Larginine was further shown to diminish KYNA synthesis by reducing the activities of KAT I and II [101, 102] .
The importance of ROS production in QUINA toxicity was also demonstrated by the finding that free radical scavengers are able to attenuate the functional structural and behavioural effect of QUINA toxicity [103, 104] .
Glutamatergic excitotoxicity
The key feature of glutamatergic neurotransmission is the rapid and efficient removal of L-Glu from the synaptic cleft with highaffinity transporters to prevent receptor over stimulation. L-Glu is taken up by the astrocytes, converted to L-glutamine, transported to the neurons and then recycled to L-Glu and finally packed into synaptic vesicles for reuse. Pathological accumulation of L-Glu leads to prolonged, tonic activation, sustained local depolarization and the influx of cations that trigger the further release of L-Glu. This vicious circle triggers intracellular events [105], primarily swelling of the neurons because of the increased cation concentration and consequent water influx, and secondly a delayed Ca 2ϩ
dependent neuronal degeneration [106] . Neuronal degeneration is mediated by calpain I, which brings about cytoskeletal breakdown [107] . Phospholipases break down the cell membranes and generate arachnoidal acid [108] , the metabolism of which generates free oxygen radicals and initiates apoptosis [109] . It has been shown that the NMDA receptor is closely linked to protein phosphatase 2A (PP2A), and stimulation of the NMDA receptor leads to the dissociation of PP2A and a reduction of the phosphatase activity [110] . This NMDA receptor-mediated mechanism may be involved in -hyperphosphorylation, a key step in the formation of neurofibrillary tangles [111] .
As mentioned above, QUINA is the direct activator of NMDA receptors [35] and the neurotoxicity of the compound in subphysiological concentrations is blocked by the NMDA receptor blockers MK-801 and memantine [112] . The neurotoxicity of QUINA was related in this experiment to the depletion of NAD ϩ , the activation of poly(ADP-ribose) polymerase, extracellular lactate dehydrogenase release and the induction of inducible and neuronal nitric oxide synthase [112] . The other possible mechanism by which QUINA induces AD pathology is PPA2-mediated -phosphorylation, which can be abrogated by memantine [111] . [113] .
Interestingly, this effect of memantine seems to be unrelated to the glycine or L-Glu binding site of the NMDA receptor as PP2A inhibition-induced hyperphosphorylation could not be prevented by the NMDA antagonist 5,7-dichlorokynurenic acid or by D(-)-2-amino-5-phosphopentanoic acid
QUINA was shown to increase the basal L-Glu release in an NMDA receptor-mediated manner [36, 114] .
QUINA not only modulates the release of L-Glu but also inhibits the uptake of L-Glu to the astrocytes, which is considered to be one of the major processes in maintaining the L-Glu concentration below toxic levels [36] . A recent experiment demonstrating that KYN pre-treatment, which presumably leads to the production of KYNA in the astrocytes, is able to prevent the neurotoxic effect of L-Glu is indicative of the potential beneficial effect of KYN in neurodegenerative diseases [115] .
Inflammation
An increased amount of reactive microglia is commonly found in the brain of AD patients [116, 117] . Most of them are around the A␤-containing compact plaques [118] [119] [120] . Both immunohistochemical and in vivo imaging studies have revealed microgliosisrelated signal changes in AD [121] . Furthermore, Edison et al. found that PET detected microglia activation, but not the amyloid burden correlated with the cognitive performance of the patients [122] . A role of the microglia has been proposed in the degradation of A␤ [123] , but microglial activation also leads to activation of the complement system and the release of cytokines, chemokines and acute phase proteins (for reviews see [124] [125] [126] [127, 129] . The abilities of macrophages and microglia to produce QUINA differ [130] ; this is related to the lower expressions of three key enzymes of the KYN pathway in the microglia: IDO, kynureninase and KYN hydroxylase [131] . A␤ is known to induce phenotypic activation of the microglia and also to modulate the acute and chronic expression of pro-inflammatory genes [132, 133] that may produce potentially toxic products. Interestingly, besides many other pro-inflammatory genes, the expressions of the enzymes of the KYN pathway are also significantly altered by A␤ [124, 132] [132] . Similarly, the expression of kynureninase was elevated (3.6- [136] [137] [138] [139] . [27, 140] . Synthetic KYNs such as KYNA are of limited therapeutic use as they penetrate the blood-brain barrier only poorly [141] , an exception being 4-Cl-KYN that readily enters the brain and is transformed to 7-Cl-KYN by KAT [142] . The systemic administration of 4-Cl-KYN increased the level of 7-Cl-KYN in the hippocampus and reduced the kainite-induced seizure activity [142] . Similarly, 4-Cl-KYN reduced the neurotoxic effect of QUINA in the rat hippocampus and striatum [143, 144] . In contrast, the synthetic KYN derivative, NMDA antagonist 5,7-dichlorokynurenic acid did not attenuate PP2A inhibition-induced -hyperphosporylation [113] . A substantial effort is being made to develop new KYNA derivatives that cross the blood-brain barrier [145] . We recently demonstrated that a novel KYN analogue, 2- (2-N,N-dimethylaminoethylamine-1-carbonyl) [147, 148] . Another such enzyme is KYN hydroxylase, loss of function mutation of which in yeast reduces mutant huntingtin fragment toxicity [149] . Ro 61-8048, a highaffinity inhibitor of KYN hydroxylase significantly reduced the mutant huntingtin-induced production of 3-OH-KYN, but not that of QUINA production, and did not ameliorated ROS production [149] . In a recent study Amori et [150] . 
. Importantly, only A␤1-42, but not A␤1-40 or A␤25-35 activated THP-1 cells (a human monocytic cell line) [134]. Administration of ␥-interferon after A␤1-42 pre-treatment, but not interleukin-1b, tumour necrosis factor-␣ or interleukin-6, induced the expression of IDO [134]. Microarray analysis of the gene expression profile of the A␤ stimulated microglia indicated an average increase of more than 40-fold (278-fold by real-time PCR) in IDO production at 24 hrs, which remained significantly elevated at 96 hrs
A future therapeutic approach: modulating the kynurenine pathway
The foregoing data indicate the significant involvement of the KYN pathway in the pathogenesis of AD. The key seems to be the shift in the TRP metabolism in the direction of neurotoxic agents and the relative reduction of neuroprotectant products. This shift has profound, but surely not independent effects on different pathomechanistic pathways in AD: oxidative stress, L-Glu neurotransmission and inflammation. Re-establishment of the physiological metabolite ratios, or even a shift of the TRP metabolism in the neuroprotectant direction may serve as a potential therapeutic approach
Concluding remarks
